Form 4: Tango Therapeutics Executive Sells Shares Under 10b5-1 Plan

Tango Therapeutics President of R&D, Adam Crystal, reported transactions involving the sale of company stock and the acquisition of stock options under a pre-arranged trading plan.

Summary

• Adam Crystal, President of R&D at Tango Therapeutics, Inc., executed several transactions on July 1, 2026.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on October 27, 2025.
• Crystal acquired 27,000 shares of common stock at a price of $5.20 per share.
• He also disposed of 19,629 shares at a weighted average price of $29.3424 and 7,371 shares at a weighted average price of $30.2464.
• Following these transactions, Crystal beneficially owns 123,114 shares of common stock directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant sale of shares by a key executive, despite the use of a 10b5-1 plan.

Positives

• The executive's acquisition of stock options indicates continued commitment and potential future upside participation.
• The sale of shares was executed under a Rule 10b5-1 plan, suggesting a pre-determined strategy for managing personal holdings and avoiding insider trading concerns.

Negatives

• A significant number of shares were sold by a key executive, which could be perceived negatively by the market.
• The sale prices, while at a premium to the acquisition price of options, represent a divestment of company stock by management.

Risks

• The Rule 10b5-1 plan itself is subject to market conditions and the executive's personal financial needs, which could lead to further sales.
• Any negative market reaction to the executive's stock sales could impact the company's share price.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance. It solely reports on past transactions by an executive.

Management Comments

• Transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.
• Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, can sometimes be interpreted by the market as a lack of confidence, although the existence of the plan mitigates this concern by demonstrating pre-planned execution.

Stakeholder Impact

• Shareholders may view the executive's stock sales with caution, potentially impacting short-term share price sentiment.
• The use of a Rule 10b5-1 plan aims to provide transparency and avoid concerns about illegal insider trading, thus maintaining confidence in corporate governance.

Next Steps

• The Rule 10b5-1 plan may continue to execute transactions as per its terms.
• The company may provide full information regarding share sales at specific prices upon request.

Key Dates

Recommendation

The filing reports routine insider transactions under a pre-established plan and does not provide new material information about the company's performance or future prospects that would warrant a change in investment strategy. Therefore, a 'hold' recommendation is appropriate, pending further company-specific developments.

Keywords

Tango Therapeutics, TNGX, Form 4, Insider Trading, Stock Options, Rule 10b5-1, Beneficial Ownership, Adam Crystal, Executive Transactions